

| Ship To:  | Patient          |             | Physician / Clini   | c 🛛 Pick l  | Jp   | Date Needed:  |                           | _ Injection Training   | Needed: 🗆 🗎 | res 📮 No                |  |
|---|------------------|-------------|---|---|--|---|---------------------------|--|-------------|-------------------------|--|
|   | Patient Name     |             |   |   |  |   |                           | Prescriber Name  |             |                         |  |
| PATIENT<br>INFORMATION  | Address          |             |   |   |  |   | . 7                       | NPI  |             |                         |  |
|   | City, State, Zip |             |   |   |  |   | BER<br>[IO]               | Address  |             |                         |  |
|   | Primary Phone    |             |   | Alt. Phone  |  |   | PRESCRIBER<br>INFORMATION | City, State, Zip   |             |                         |  |
|   | Date of Birth    |             |   | Allergies   |  |   | RES(                      | Office Phone:  |             |                         |  |
|   | Height/ Weight   |             |   | Sex:  |  | <ul><li>Male</li><li>Female</li></ul>   | PF<br>INF                 | Office Fax:  |             |                         |  |
|   | Insurance        |             | PLEASE FA   | FAX A COPY OF INSU  |  | IRANCE CARD(S)  |                           | Contact Person   |             |                         |  |
| CLINICAL INFORMATION  |                  |             |   |   |  |   |                           |  |             |                         |  |
| Diagnosis   | : 🗆 Psoriasis 🗆  | Psori       | iatic Arthritis 🛛 Ec  | c Arthritis 🗖 Eczema 📮 Atopic Dermatitis ICD10 Code: 🗖 Other: Disease |  |   |                           |  |             | ild 🛛 Moderate 🖓 Severe |  |
| PPD/Ches  | st X-Ray for TB  |             | Yes Date of Negative TB test:   |   |  |   | % E                       | % BSA Affected by Psoriasis: $\Box > 5\%$ $\Box < 5\%$ $\Box$ Other: |             |                         |  |
| Hepatitis B Test: Does patient Does patient have CHF D Yes D No Does patient have active infection/malignancy? D Yes D No |                  |             |   |   |  |   |                           |  |             | y? 🗖 Yes 🗖 No           |  |
| Tried/Fai   | led Previous Th  | ıerapi      | pies: DMARDS 🛛 Yes 🗋 No Please List: If no, please explain why  |   |  |   |                           |  | ıy:         |                         |  |
| Biologics: 🛛 Yes 🗋 No Please List:  |                  |             |   |   |  |   |                           |  |             |                         |  |
| MEDI  | ICATION          | Г           | DOSE/ STRENGTH  |   | PRI  | ESCRIPTION INFO   |                           | HON  | QUANTITY    | REFILLS                 |  |
| WIED  | ICATION          |             | imzia Starter Kit   |   | DIRECTIONS<br>Induction Dose: Inject 400 mg SC on day 1, and   |   |                           |  | Quintin     | KEITELS                 |  |
|   | <b>.</b> .       | (6          | 6 prefilled syringes) week 2, and at week 4   |   |  |   |                           |  |             |                         |  |
| CIMZI   | IA               |             | 00 mg/1mL PFS       Image: Maintenance Dose: Inject 200 mg SC every other week         Image: Maintenance Dose: Inject 400 mg SC every 4 weeks         Image: Other: Inject 400 mg SC every 4 weeks |   |  |   |                           |  |             |                         |  |
| COSENTYX  |                  |             | 50 mg/mL PFS<br>50 mg/mL PEN  | 1,  | <ul> <li>Induction Dose: Inject 300 mg (2 injections of 150mg) SQ at week 0, 1, 2, 3, and 4 then 300mg SQ every 4 weeks</li> <li>Maintenance Dose: Inject 300mg SQ every 4 weeks</li> </ul>  |   |                           |  |             |                         |  |
| • ENBREL  |                  | □ 2:<br>□ 5 | 5 mg vial<br>5 mg/0.5mL PFS<br>0 mg/mL Sureclick<br>0 mg/mL PFS   | 🗖 Inje  | <ul> <li>Inject 25 mg SC twice weekly (72 to 96 hrs apart)</li> <li>Inject 50 mg SC once weekly</li> <li>Other:</li> </ul>   |   |                           |  |             |                         |  |
| HUMIRA  |                  | <b>4</b>    | 0 mg/0.8ml Starter I<br>0 mg/0.8mL PFS<br>0 mg/0.8mL PEN  | 🗖 Inje  | <ul> <li>□ Inject 80 mg SQ day 0, then 40mg day 7, then 40mg every other week</li> <li>□ Inject 40 mg SC every other week</li> <li>□ Other:</li> </ul>   |   |                           |  |             |                         |  |
| OTEZLA  |                  | D T         | itration Starter Pack   | Da<br>Da<br>Da  | <ul> <li>Day 1: Take 10mg po QAM</li> <li>Day 2: Take 10mg po BID</li> <li>Day 3: Take 10mg po QAM and 20mg po QPM</li> <li>Day 4: Take 20mg po BID</li> <li>Day 5: Take 20mg po QAM and 30mg po QPM then take 30mg</li> <li>BID thereafter</li> </ul>                               |   |                           |  |             |                         |  |
|   |                  | <b>3</b>    | 0 mg tablets  |   | Take 30 mg by mouth twice daily  |   |                           |  |             |                         |  |
| SILIQ   |                  | <b>D</b> 2  | 10 mg/1.5mL PFS   |   | □ Inject 210 mg SQ at weeks 0, 1, then every 2 weeks thereafter<br>(Prescriber must be certified to prescribe SILIQ)   |   |                           |  |             |                         |  |
|   |                  |             | 0 mg/0.5mL SmartJ<br>0 mg/0.5mL PFF   |   | □ Inject 50 mg SC once every month   |   |                           |  |             |                         |  |
| STELARA   |                  |             | 5 mg/0.5mL PFS<br>0 mg/mL PFS   | 4 w<br>G For<br>4 w   | <ul> <li>□ For patients weighing ≤ 100 kg (220 lbs): Inject 45 mg SC initially and 4 weeks later, followed by 45 mg every 12 weeks</li> <li>□ For patients weighing &gt; 100 kg (220 lbs): Inject 90 mg SC initially and 4 weeks later, followed by 90 mg every 12 weeks.</li> </ul> |   |                           |  |             |                         |  |
| TALTZ   |                  | <b>a</b> 80 | Omg   | We  | eks 2,   | 0 mg (two 80 mg injection<br>4, 6, 8, 10, and 12, then 8<br>0 mg SC at Week 0, then 8 |                           |  |             |                         |  |
| TREMFYA   |                  | <b>□</b> 10 | 00 mg/mL PFS  |   | □ Inject 100 mg SQ at week 0, 4, and every 8 weeks thereafter  |   |                           |  |             |                         |  |
| DUPIXENT  |                  | □ 3         | 00 mg/2mL PFS   |   |  | se 600mg (2 syringes) SC<br>SC every 2 weeks  | week 0, 1                 | followed by 300mg (1   |             |                         |  |
| <b>EUCRISA</b>  |                  | 2           | % ointment  | D Ap  | ply a t  | thin layer of Eucrisa to the  | affected                  | area(s) twice daily  |             |                         |  |
| OTHE  | R                |             |   |   |  |   |                           |  |             |                         |  |

By signing below, I authorize El Norte Pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization process and help the patient to apply to co-pay assistance programs, including all foundations and manufacturer assistance programs if necessary.

Prescriber Signature:

Date: \_

This fax transmission may contain confidential information belonging to the sender which is legally privileged. This information is intended only for the use of the recipient named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the consents of this faxed information is strictly prohibited. Please notify us by phone to arrange for the return of the original documents.